York, U.K. 5 March 2026: Abingdon Health plc (AIM: ABDX), a leading international developer, manufacturer and regulatory services provider for rapid diagnostic tests and med-tech, will announce its interim results for the six months ended 31 December 2025 on Tuesday 17 March 2026.
Investor Presentation
The Company will provide a live online presentation relating to the interim results via the Investor Meet Company platform on Tuesday 17 March 2026 at 11:00 GMT. The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via the Investor Meet Company dashboard up until 09:00 GMT the day before the meeting or at any time during the live presentation.
Investors can sign up to Investor Meet Company for free and add to meet Abingdon Health plc via: https://www.investormeetcompany.com/abingdon-health-plc/register-investor
Investors who already follow Abingdon Health plc on the Investor Meet Company platform will automatically be invited.
Enquiries
|
Abingdon Health plc |
||
|
Chris Hand, Executive Chairman |
Via Walbrook PR |
|
|
Tom Hayes, CFO |
||
|
Cavendish Capital Markets Limited (Sole Broker and Nominated Adviser) |
Tel: +44 (0)20 7220 0500 |
|
|
Geoff Nash / Isaac Hooper / Joe Smith (Corporate Finance) |
||
|
Nigel Birks (Life Science Specialist Sales) |
||
|
Walbrook PR (Media & Investor Relations) |
Tel: +44 (0)20 7933 8780 or [email protected] |
|
|
Paul McManus / Alice Woodings |
Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654 | |
